Table 1 Baseline characteristics of the study cohort according to squamous cell carcinoma and adenocarcinoma histology.

From: A prognostic score for non-small cell lung cancer resected after neoadjuvant therapy in comparison with the tumor-node-metastases classification and major pathological response

 

SQCC

ADC

p-Value

Other

 

(n = 54)

(n = 56)

(n = 7)

Age, years (median [IQR])

63[55.25–69.75]

62[55.75–68.25]

0.788a

68[59–71]

Smoking status

n = 48 (%)

n = 49 (%)

0.193b

n = 6 (%)

 Non-smoker

3(6.2)

9(18.4)

 

2(33.3)

 Ex-smoker

27(37.5)

22(44.9)

 

4(66.7)

 Active smoker

18(56.2)

18(36.7)

  

Macroscopic tumor bed, cm (median [IQR])

3.5[2.58–5.42]

3.5[2.38–4.20]

0.385a

4[1.9–4.35]

Adjusted tumor size, cm (median [IQR])

1.24[0.06–2.76]

1.78[0.05–2.95]

0.832a

0[0–3.16]

ypT-TNM8

n = 54 (%)

n = 56 (%)

0.805a

n = 7 (%)

 ypT0

6(11.1)

5(8.9)

 

4(57.1)

 ypT1

14(25.9)

19(33.9)

  

 ypT2a

11(20.4)

9(16.1)

  

 ypT2b

3(5.6)

3(5.4)

 

1(14.3)

 ypT3

6(11.1)

13(23.2)

 

1(14.3)

 ypT4

14(25.9)

7(12.5)

 

1(14.3)

TNM8

n = 54 (%)

n = 56 (%)

0.557a

n = 7 (%)

 No vital tumor

3(5.6)

3(5.4)

 

4(57.1)

 Stage I

10(18.5)

12(21.4)

  

 Stage II

14(25.9)

11(19.7)

  

 Stage III

26(48.1)

26(46.4)

 

3(42.9)

 Stage IV

1(1.9)

4(7.1)

  

Regression

n = 54 (%)

n = 56 (%)

0.460a

n = 7 (%)

 pCR

3(5.6)

4(7.1)

 

4(57.1)

 <1%

9(16.7)

9(16.1)

  

 1–10%

9(16.7)

6(10.7)

  

 11–49%

9(16.7)

6(10.7)

 

1(14.3)

 ≥50%

24(44.3)

31(55.4)

 

2(28.6)

PRSC

n = 54 (%)

n = 56 (%)

0.332a

n = 7 (%)

 Low risk

23(42.6)

21(37.5)

 

4(57.1)

 Intermediate risk

14(25.9)

25(44.6)

 

1(14.3)

 High risk

17(31.5)

10(17.9)

 

2(28.6)

Neoadjuvant chemotherapy

n = 53 (%)

n = 55 (%)

0.551b

n = 7 (%)

 Cisplatin + docetaxel

31(58.5)

31(56.4)

 

6(85.7)

 Carboplatin + paclitaxel

3(5.7)

2(3.6)

  

 Cisplatin + pemetrexed

6(11.3)

7(12.7)

  

 Cisplatin + gemcitabin

6(11.3)

3(5.5)

  

 Cisplatin + vinorelbin

2(3.8)

7(12.7)

 

1(14.3)

 Cisplatin + etoposid

 

1(1.8)

  

 Other

5(9.4)

4(7.3)

  

Neoadjuvant radiotherapy

n = 50 (%)

n = 54 (%)

0.689b

n = 7 (%)

 No

38(76)

38(70.4)

 

4(57.1)

 Yes

12(24)

16(29.6)

 

3(42.9)

Surgical procedure

n = 54 (%)

n = 56 (%)

0.001b

n = 7 (%)

 Lobectomy

23(42.6)

42(75)

 

4(57.1)

 Bilobectomy

4(7.4)

1(1.8)

  

 Pneumonectomy

27(50)

13(23.2)

 

3(42.9)

R

n = 53 (%)

n = 55 (%)

0.031b

n = 7 (%)

 R0

41(77.4)

51(92.7)

 

7(100)

 R1

12(22.6)

4(7.3)

  
  1. SQCC squamous cell carcinoma, ADC adenocarcinoma, ypT-TNM8 ypT according TNM eighth edition, TNM8 stages according TNM eighth edition, pCR pathological complete response, PRSC prognostic score.
  2. aMann–Whitney-U test.
  3. bFisher’s exact test.